Moderna Vaccine Shows Positive Sign In Human Trial

Moderna Inc. has developed an experimental vaccine for COVID-19 that showed positive signs, which can develop an immune-system response in the body. This immune-system response can help fend off the highly infectious disease, coronavirus. Moderna reported this update after the first successful human trial that was conducted on a small bunch of healthy people.

Eight patients who underwent the human trial of Moderna's vaccine showed to develop anti-bodies that look similar to the blood samples of the patients who have recovered from COVID-19. 

Moderna vaccine can be considered as a crucial step and hopeful breakthrough that could help towards lifting social-distancing and result in reopening economies around the globe.

See What Moderna Inc. Reported

The company shall soon share full results from the human trial later in further development. The researchers at Moderna also looked at blood samples of the human trials to check whether the Moderna vaccine helped them develop/generate antibodies that could fight the highly infectious, COVID-19. The researchers found that two-dose levels were used in the study, and the progressive results were seen after the second booster shot of the vaccine that resulted in either equal or exceeded the levels of antibodies found in the coronavirus recovered patients.

“This is a very good sign that we make an antibody that can stop the virus from replicating," Moderna Chief Executive Officer Stephane Bancel said in an interview. The data “couldn't have been better," he said.

Bancel said that, "The safety profile appeared to be good, and the reactions were typical of vaccines. They included injection site pain and redness, as well as temporary fever or chills that quickly go away on their own."

Bancel further added- the company felt the need to release the interim data from the human trial because of the high level of interest in the corona vaccine. A phase 2 trial is expected to begin shortly, and Moderna said in its statement that a final-stage trial will begin in July. Bancel said the phase 3 trial will likely include many thousands of healthy volunteers.

"We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2," Moderna Chief Executive Officer Stéphane Bancel said.

This very early data offers a ray of hope and can be amongst the most advanced in the development of corona vaccine. Currently, there are no approved vaccine or treatments for this highly-infectious disease, COVID-19. The experts predicted earlier that a safe and full-proof vaccine could take around 12-18 months.